Goldman Sachs Removed Charles River Labs (CRL) from its Conviction Sell List
More News related to CRL
- Barclays Downgrades Charles River Labs (CRL) to Equal Weight
- Morning Movers 11/04: MPAC, ABK, GNVC, RHB, IRE, PACR Higher; STEC, CLRT, VG, TRLG, ANSW Lower
- After-Hours Movers 11/03: QLTY, PACR, BGCP, TESO Higher; STEC, TRLG, CLRT, CRL, MYGN Lower
- Charles River (CRL) Beats Q3 Views by 5c; Lowers FY09 EPS Guidance
- Charles River Announces Third-Quarter 2009 Results
More News related to Analyst Comments
- Top 10 News Items 11/30-12/04: Non-Farm Payrolls Much Better-Than-Expected, Comcast to Take 51% Stake in NBC Universal, BofA to Repay $45B in TARP Funds
- Trading Radar for 12/7: Kroger (KR), Pep Boys (PBY), Krispy Kreme (KKD), Casey's General Stores (CASY) Report
- Unusual 11 Mid-Day Movers 12/04: BIG, FLOW, SNV, OCLS Higher; TTWO, ZIOP, VSNT, SWHC Lower
- Notable ETF Movers 12/04: UUP, UNG Up; XME, GDX, GLD, SLV Down
- Notable Analyst Rating Changes 12/04: BAC, SNV, FSLR, AKAM Upgraded; TTWO, SWHC, AKS, NFLX Downgraded
Goldman Sachs removed Charles River Laboratories International Inc. (NYSE: CRL) from its Conviction Sell List. The firm is maintaining a Sell rating on the shares.
Charles River Laboratories International, Inc., together with its subsidiaries, provides solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services worldwide.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsStocks Mentioned
-0.18Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
